Activin and Inhibin

DC_517 is a DNA methyltransferase 1 ( DNMT1 ) inhibitor, with an IC 50 and a K d of 1.7 μM and 0.91 μM, respectively.In VitroDC_517 is a DNA methyltransferase 1 (DNMT1) inhibitor, with an IC 50 and a K d of 1.7 μM and 0.91 μM, respectively. DC_517

DC_517 is a DNA methyltransferase 1 ( DNMT1 ) inhibitor, with an IC 50 and a K d of 1.7 μM and 0.91 μM, respectively.In VitroDC_517 is a DNA methyltransferase 1 (DNMT1) inhibitor, with an IC 50 and a K d of 1.7 μM and 0.91 μM, respectively. DC_517

DC_517 is a DNA methyltransferase 1 ( DNMT1 ) inhibitor, with an IC 50 and a K d of 1.7 μM and 0.91 μM, respectively.In VitroDC_517 is a DNA methyltransferase 1 (DNMT1) inhibitor, with an IC 50 and a K d of 1.7 μM and 0.91 μM, respectively. DC_517

DC_AC50 is a dual inhibitor of Atox1 and CCS (copper chaperones). Inhibiting intracellular copper chaperones as a means of reducing/preventing acquired chemotherapy resistance.In VitroDC_AC50 exhibits IC 50 values of 9.88 μM, 12.57 μM, 5.96 μM and

DC_AC50 is a dual inhibitor of Atox1 and CCS (copper chaperones). Inhibiting intracellular copper chaperones as a means of reducing/preventing acquired chemotherapy resistance.In VitroDC_AC50 exhibits IC 50 values of 9.88 μM, 12.57 μM, 5.96 μM and

DC_AC50 is a dual inhibitor of Atox1 and CCS (copper chaperones). Inhibiting intracellular copper chaperones as a means of reducing/preventing acquired chemotherapy resistance.In VitroDC_AC50 exhibits IC 50 values of 9.88 μM, 12.57 μM, 5.96 μM and

DC_AC50 is a dual inhibitor of Atox1 and CCS (copper chaperones). Inhibiting intracellular copper chaperones as a means of reducing/preventing acquired chemotherapy resistance.In VitroDC_AC50 exhibits IC 50 values of 9.88 μM, 12.57 μM, 5.96 μM and

DC_AC50 is a dual inhibitor of Atox1 and CCS (copper chaperones). Inhibiting intracellular copper chaperones as a means of reducing/preventing acquired chemotherapy resistance.In VitroDC_AC50 exhibits IC 50 values of 9.88 μM, 12.57 μM, 5.96 μM and

DCH36_06 is a potent and selective p300/CBP inhibitor with IC 50 s of 0.6 μM and 3.2 μM for p300 and CBP , respectively. DCH36_06 mediated p300/CBP inhibition leading to hypoacetylation on H3K18 in leukemic cells. Anti-tumor activity.In

DCH36_06 is a potent and selective p300/CBP inhibitor with IC 50 s of 0.6 μM and 3.2 μM for p300 and CBP , respectively. DCH36_06 mediated p300/CBP inhibition leading to hypoacetylation on H3K18 in leukemic cells. Anti-tumor activity.In

DCH36_06 is a potent and selective p300/CBP inhibitor with IC 50 s of 0.6 μM and 3.2 μM for p300 and CBP , respectively. DCH36_06 mediated p300/CBP inhibition leading to hypoacetylation on H3K18 in leukemic cells. Anti-tumor activity.In

DCH36_06 is a potent and selective p300/CBP inhibitor with IC 50 s of 0.6 μM and 3.2 μM for p300 and CBP , respectively. DCH36_06 mediated p300/CBP inhibition leading to hypoacetylation on H3K18 in leukemic cells. Anti-tumor activity.In